Compare Enovix Corporation (ENVX) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Medpace Holdings Inc — how do they compare? Enovix Corporation trades at $4.86 (market cap $1.11B), while Medpace Holdings Inc trades at $535.81 (market cap $15.11B). The key difference: Medpace Holdings Inc is far larger — about 13.6× Enovix Corporation's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ENVX | MEDP | |
|---|---|---|
Market Cap | $1.11B | $15.11B |
Sector | Technology | Technology |
52-Week High | $15.93 | $620.59 |
52-Week Low | $4.84 | $308.88 |
Enterprise Value | $1.13B | $14.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.855, down 4.05% today amid bearish technical signals. The company shows strong revenue growth potential with recent earnings beats but operates at a significant loss, reflected in a -499.64% net margin. Positive sentiment is driven by analyst consensus with a $12.75 price target and recent operational hires from Apple, though cash flow remains negative as production scales.
Outlook hinges on successful manufacturing ramp-up and smartphone battery qualification. High execution risk and cash burn present challenges, but leadership in silicon-anode technology offers long-term upside if commercial targets are met. Investors face volatility but potential reward from current discounted levels.
Medpace (MEDP) trades at $534.85, down 0.25% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. The company shows strong profitability with a 17.19% net income margin and 77.25% ROE, though valuations are elevated with a P/E of 33.31. Recent earnings have consistently beaten estimates, and cash flow is projected to improve in 2026. News highlights focus on CRO demand shifts and a class action lawsuit from June 2026.
Outlook remains mixed; strong earnings momentum and operational efficiency support upside, but high valuation and legal overhangs pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term appreciation potential amid balanced investor sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
